Advances in sodium-glucose transporter protein 2 inhibitors and tumors
Tumor is a major challenge to global health and has received extensive attention worldwide due to its high degree of malignancy and poor prognosis. Although the clinical application of targeted therapy and immunotherapy has improved the status quo of tumor treatment, the development of new therapeut...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1522059/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859404718473216 |
|---|---|
| author | Jiaqi Wang Wenyong Yang |
| author_facet | Jiaqi Wang Wenyong Yang |
| author_sort | Jiaqi Wang |
| collection | DOAJ |
| description | Tumor is a major challenge to global health and has received extensive attention worldwide due to its high degree of malignancy and poor prognosis. Although the clinical application of targeted therapy and immunotherapy has improved the status quo of tumor treatment, the development of new therapeutic tools for tumors is still necessary. Sodium-glucose transporter protein 2 (SGLT2) inhibitors are a new type of glycemic control drugs, which are widely used in clinical practice because of their effects on weight reduction and protection of cardiac and renal functions. SGLT2 has been found to be overexpressed in many tumors and involved in tumorigenesis, progression and metastasis, suggesting that SGLT2i has a wide range of applications in tumor therapy. The aim of this article is to provide a comprehensive understanding of the research progress of SGLT2i in different tumors by integrating the latest studies and to encourage further exploration of SGLT2i therapies in clinical trials. This could pave the way for more effective management strategies and improved outcomes for tumor patients. |
| format | Article |
| id | doaj-art-7b799b860d3d4c648deb3a3d5a80ca60 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-7b799b860d3d4c648deb3a3d5a80ca602025-02-11T05:10:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.15220591522059Advances in sodium-glucose transporter protein 2 inhibitors and tumorsJiaqi Wang0Wenyong Yang1Department of Oncology, Guangyuan Central Hospital, Guangyuan, Sichuan, ChinaDepartment of Respiratory and Critical Care Medicine, Guangyuan Central Hospital, Guangyuan, Sichuan, ChinaTumor is a major challenge to global health and has received extensive attention worldwide due to its high degree of malignancy and poor prognosis. Although the clinical application of targeted therapy and immunotherapy has improved the status quo of tumor treatment, the development of new therapeutic tools for tumors is still necessary. Sodium-glucose transporter protein 2 (SGLT2) inhibitors are a new type of glycemic control drugs, which are widely used in clinical practice because of their effects on weight reduction and protection of cardiac and renal functions. SGLT2 has been found to be overexpressed in many tumors and involved in tumorigenesis, progression and metastasis, suggesting that SGLT2i has a wide range of applications in tumor therapy. The aim of this article is to provide a comprehensive understanding of the research progress of SGLT2i in different tumors by integrating the latest studies and to encourage further exploration of SGLT2i therapies in clinical trials. This could pave the way for more effective management strategies and improved outcomes for tumor patients.https://www.frontiersin.org/articles/10.3389/fonc.2025.1522059/fullSGLT2icancerdiabeticchemotherapy side effectscarcinogenicity |
| spellingShingle | Jiaqi Wang Wenyong Yang Advances in sodium-glucose transporter protein 2 inhibitors and tumors Frontiers in Oncology SGLT2i cancer diabetic chemotherapy side effects carcinogenicity |
| title | Advances in sodium-glucose transporter protein 2 inhibitors and tumors |
| title_full | Advances in sodium-glucose transporter protein 2 inhibitors and tumors |
| title_fullStr | Advances in sodium-glucose transporter protein 2 inhibitors and tumors |
| title_full_unstemmed | Advances in sodium-glucose transporter protein 2 inhibitors and tumors |
| title_short | Advances in sodium-glucose transporter protein 2 inhibitors and tumors |
| title_sort | advances in sodium glucose transporter protein 2 inhibitors and tumors |
| topic | SGLT2i cancer diabetic chemotherapy side effects carcinogenicity |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1522059/full |
| work_keys_str_mv | AT jiaqiwang advancesinsodiumglucosetransporterprotein2inhibitorsandtumors AT wenyongyang advancesinsodiumglucosetransporterprotein2inhibitorsandtumors |